OTCMKTS:ENDVEndonovo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Endonovo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.12 +0.02 (+16.08 %) (As of 08/14/2020 01:22 PM ET) Add Compare Share Today's Range$0.10Now: $0.12▼$0.1250-Day Range$0.09MA: $0.10▼$0.1352-Week Range$0.01Now: $0.12▼$13.40Volume9,640 shsAverage Volume142,311 shsMarket Capitalization$118.70 millionP/E RatioN/ADividend YieldN/ABeta2.12 ProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestSocial Media Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Endonovo Therapeutics. Previous Next 2.1 Community Rank Outperform VotesEndonovo Therapeutics has received 81 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEndonovo Therapeutics has received 110 “underperform” votes. (Add your “underperform” vote.)Community SentimentEndonovo Therapeutics has received 57.59% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Endonovo Therapeutics and other stocks. Vote “Outperform” if you believe ENDV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENDV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEndonovo Therapeutics does not currently pay a dividend.Dividend GrowthEndonovo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Endonovo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.61% of the stock of Endonovo Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ENDV Previous Symbol CUSIPN/A CIK1528172 Webwww.endonovo.com Phone800-489-4774Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales1,483.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.95Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,440,000.00 Net Margins-5,033.33% Return on EquityN/A Return on Assets-264.21%Miscellaneous EmployeesN/A Outstanding Shares1,002,549,000Market Cap$118.70 million Next Earnings DateN/A OptionableNot Optionable $0.12 +0.02 (+16.08 %) (As of 08/14/2020 01:22 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ENDV News and Ratings via Email Sign-up to receive the latest news and ratings for ENDV and its competitors with MarketBeat's FREE daily newsletter. Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions How has Endonovo Therapeutics' stock price been impacted by Coronavirus (COVID-19)? Endonovo Therapeutics' stock was trading at $0.3150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENDV stock has decreased by 62.4% and is now trading at $0.1184. View which stocks have been most impacted by COVID-19. Has Endonovo Therapeutics been receiving favorable news coverage? Media headlines about ENDV stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endonovo Therapeutics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news about Endonovo Therapeutics. Are investors shorting Endonovo Therapeutics? Endonovo Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 22,000 shares, an increase of 315.1% from the June 15th total of 5,300 shares. Based on an average daily volume of 251,800 shares, the short-interest ratio is currently 0.1 days. View Endonovo Therapeutics' Short Interest. Who are some of Endonovo Therapeutics' key competitors? Some companies that are related to Endonovo Therapeutics include ANI Pharmaceuticals (ANIP), 89bio (ETNB), Puma Biotechnology (PBYI), Avedro (AVDR), Albireo Pharma (ALBO), Satsuma Pharmaceuticals (STSA), CymaBay Therapeutics (CBAY), Atreca (BCEL), Liminal BioSciences (LMNL), Ovid Therapeutics (OVID), Xenon Pharmaceuticals (XENE), Clovis Oncology (CLVS), Amryt Pharma (AMYT), Merus (MRUS) and Kamada (KMDA). View all competitors. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Energous (WATT), BIOLINERX LTD/S (BLRX), Ekso Bionics (EKSO), Marinus Pharmaceuticals (MRNS), Adamis Pharmaceuticals (ADMP), Advanced Micro Devices (AMD), Apache (APA) and Athersys (ATHX). Who are Endonovo Therapeutics' key executives? Endonovo Therapeutics' management team includes the following people: Mr. Alan Brian Collier, Chairman, CEO, Interim CFO & Sec. (Age 53)Mr. Michael Scott Mann, Pres (Age 62)Mr. Donald Calabria, Chief Operating OfficerMr. Steven Barnes, Sr. VP of Investor RelationsBruce Garfield, Vice-Pres of Sales & Marketing What is Endonovo Therapeutics' stock symbol? Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV." How do I buy shares of Endonovo Therapeutics? Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Endonovo Therapeutics' stock price today? One share of ENDV stock can currently be purchased for approximately $0.12. How big of a company is Endonovo Therapeutics? Endonovo Therapeutics has a market capitalization of $118.70 million and generates $80,000.00 in revenue each year. What is Endonovo Therapeutics' official website? The official website for Endonovo Therapeutics is www.endonovo.com. How can I contact Endonovo Therapeutics? Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at 800-489-4774 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
